WIRB-Copernicus Group Acquires Vigilare International

Published on: 

Applied Clinical Trials

WIRB Copernicus Group® announced its acquirement of Vigilare International, a provider of integrated, end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry. This new acquistion is a perfect fit for both companies as Vigilare compliments WCG's existing clinical research solutions and they plan to identify more opportunities to streamline clinical research operations.

Read the full release here.